Tuesday, June 16, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Locally Advanced Non-Small Cell Lung Cancer


Benjamin Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Medical Director, Thoracic Oncology Program
Johns Hopkins Sidney Kimmel Cancer Center at
Sibley Memorial
Washington, DC

Stephen V Liu, MD, PhD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC

Beth Sandy, MSN, CRNP
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Elizabeth S Waxman, RN, MSN, ANP-BC
Nurse Practitioner in the Department of
Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Historical outcomes associated with standard concurrent chemoradiation therapy and consolidation chemotherapy in patients with unresectable Stage III non-small cell lung cancer (NSCLC)
  • Biologic rationale for the evaluation of immune checkpoint inhibitors for patients with Stage III disease who are undergoing chemoradiation therapy
  • Key efficacy findings with consolidation durvalumab after chemoradiation therapy for unresectable Stage III NSCLC; patient selection for and practical implementation of sequential durvalumab in the management of unresectable Stage III NSCLC
  • Efficacy and current role of durvalumab in prespecified disease subgroups (eg, by histology, smoking status, PD-L1 status, targetable genomic alteration)
  • Optimal timing for durvalumab consolidation therapy and the impact of underlying radiation therapy-induced toxicities (eg, pneumonitis, esophagitis) on the decision to introduce this therapy
  • Rates of Grade 3 or 4 adverse events, including pneumonitis and other immune-mediated toxicities, among patients receiving consolidation durvalumab
  • Optimal monitoring for immune-mediated adverse events in patients receiving consolidation durvalumab; supportive care protocols and indications for withholding or discontinuing therapy

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Appreciate the benefits, risks and long-term outcomes associated with current local and/or systemic treatment modalities in the management of resectable or unresectable locally advanced non-small cell lung cancer (NSCLC), and consider this information when counseling patients.
  • Review the FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Develop an understanding of which clinical and biologic factors (eg, chemoradiation therapy-related toxicities, PD-L1 status, EGFR/ALK status) potentially affect the decision to use anti-PD-L1 antibody consolidation for unresectable Stage III NSCLC, and apply this information to better counsel patients about current therapeutic recommendations.
  • Recognize immune-related adverse events and other common side effects of anti-PD-L1 antibody consolidation therapy in patients with Stage III NSCLC, and offer supportive strategies to minimize and manage these toxicities.
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for localized or locally advanced NSCLC, and counsel appropriate patients about availability and participation.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with locally advanced NSCLC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2020/LocallyAdvancedNSCLC/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Waxman has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr LevyConsulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Lilly, Merck, Pfizer Inc, Takeda Oncology; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Lilly. Dr LiuAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, G1 Therapeutics, Genentech, a member of the Roche Group, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Merck Sharp & Dohme Corp, Pfizer Inc, Takeda Oncology; Contracted Research: Alkermes, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Genentech, a member of the Roche Group, Lilly, Lycera, Merck, Merus BV, Molecular Partners, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Spectrum Pharmaceuticals Inc, Turning Point Therapeutics; Data and Safety Monitoring Board/Committee: Taiho Oncology Inc. Ms SandySpeakers Bureau: AstraZeneca Pharmaceuticals LP, Helsinn Group, Merck, Takeda Oncology.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.